Bausch Health (NYSE:BHC) along with its subsidiary, Salix Pharmaceuticals has filed a lawsuit against Sandoz Inc., a Novartis (NYSE:NVS) division, alleging patent infringement of 14 patents by Sandoz’s filing of its ANDA for XIFAXAN (rifaximin) 550 mg tablets.
XIFAXAN is protected by 22 patents covering the
composition of matter and use listed in the FDA Approved Drug Products
with Therapeutic Equivalence Evaluations, or the Orange Book.
In September 2018, BHC resolved the outstanding patent dispute with Actavis Laboratories, regarding XIFAXAN 550 mg tablets.
BHC shares are down 1% premarket.
https://seekingalpha.com/news/3502817-bausch-health-files-lawsuit-sandoz-patent-infringement
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.